One-Time CRISPR Injection Permanently Lowers Cholesterol by 55%

How Does CRISPR Cholesterol Treatment Work?

VERVE-101 represents a fundamentally new approach to cardiovascular disease prevention. Rather than requiring lifelong medication to suppress cholesterol production or enhance LDL clearance, the therapy makes a permanent genetic change in hepatocytes (liver cells) that durably reduces LDL cholesterol. The treatment is delivered as a one-time intravenous infusion of lipid nanoparticles (LNPs) that are naturally taken up by the liver, where they release their cargo: mRNA encoding an adenine base editor and a guide RNA targeting the PCSK9 gene.

The adenine base editor makes a precise A-to-G change at a specific position in the PCSK9 gene, introducing a loss-of-function variant that prevents the liver from producing functional PCSK9 protein. PCSK9 normally binds to LDL receptors on hepatocytes and promotes their degradation; without PCSK9, LDL receptors accumulate on the cell surface and clear more LDL cholesterol from the bloodstream. This mechanism is well-validated: naturally occurring PCSK9 loss-of-function mutations have been found in population studies and are associated with significantly lower LDL cholesterol and substantially reduced coronary heart disease risk, with no adverse health consequences. A landmark 2006 study in the New England Journal of Medicine found that certain PCSK9 variants were linked to 28% lower LDL and up to 88% lower coronary heart disease risk.

Critically, base editing does not create double-strand DNA breaks (unlike traditional CRISPR-Cas9), avoiding the risks of insertions, deletions, and chromosomal rearrangements. The editing occurs only in the liver cells that take up the LNPs, and the mRNA and guide RNA are degraded within hours — the editing machinery does not persist, reducing the risk of off-target effects. In preclinical primate studies published in Nature, whole-genome sequencing of treated samples showed off-target editing rates below the limit of detection.

What Were the Clinical Trial Results?

The HEART-1 phase 1b trial enrolled patients with heterozygous familial hypercholesterolemia (HeFH) and established atherosclerotic cardiovascular disease (ASCVD) who had elevated LDL cholesterol despite maximally tolerated lipid-lowering therapy. Participants received a single intravenous infusion of VERVE-101 at escalating doses across multiple cohorts. Initial data presented at the American Heart Association Scientific Sessions showed that a lower-dose cohort achieved approximately 39% LDL cholesterol reduction, with higher-dose cohorts reported to achieve up to 55% reduction as the trial progressed to optimal dosing.

Blood PCSK9 protein levels were substantially reduced across dose cohorts, confirming effective in vivo gene editing. Liver function tests showed transient, mild elevations in ALT and AST (liver enzymes) in some participants, which resolved spontaneously. The trial has included serious adverse events — including one patient death from cardiac arrest — though this occurred in a participant with severe pre-existing cardiovascular disease, and the relationship to the study drug remains a subject of ongoing evaluation. Comprehensive genomic analyses have not detected clinically significant off-target editing.

The LDL reductions achieved at higher doses are comparable to the reductions seen with high-intensity statin therapy (approximately 50% with rosuvastatin 40mg) or PCSK9 monoclonal antibodies like evolocumab and alirocumab (approximately 55-60%). However, the transformative potential lies in durability — if the effect proves permanent, as expected given the mechanism of irreversible gene editing, it would replace decades of daily medication with a single procedure. Verve Therapeutics continues to advance the HEART-1 program and has indicated plans to evaluate the therapy in broader populations with elevated cardiovascular risk.